Core Viewpoint - The company,药捷安康-B (02617.HK), has announced a placement agreement with CITIC Securities to issue 2.1 million shares at a price of HKD 92.85 per share, representing a discount of approximately 17.98% from the closing price of HKD 113.20 on January 13 [1] Group 1 - The placement shares represent about 0.70% of the existing issued H shares and 0.53% of the total issued shares as of the announcement date [1] - The expected total gross proceeds from the placement are approximately HKD 194.99 million, with net proceeds estimated at around HKD 190.14 million [1] Group 2 - The company plans to allocate approximately 60% of the net proceeds to fund clinical trials for its core product, Tinengotinib, in treating cholangiocarcinoma (CCA) and other indications [1] - About 30% of the net proceeds will be used for the development of other products, including TT-00973, TT-01488, and other molecules [1] - The remaining 10% of the net proceeds will be allocated for working capital and general corporate purposes [1]
药捷安康-B(02617.HK)拟配售210万股 总筹1.95亿港元